Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.
BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations
Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...